CD274 and neoplasm: The most extensively studied biomarkers for anti-PD-1/PD-L1 therapy include tumor mutation burden (TMB), expression of PD-L1 in tumor/immune cells and expression patterns of immune-related genes in the tumor microenvironment (14–16).